JP2012517223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517223A5 JP2012517223A5 JP2011548901A JP2011548901A JP2012517223A5 JP 2012517223 A5 JP2012517223 A5 JP 2012517223A5 JP 2011548901 A JP2011548901 A JP 2011548901A JP 2011548901 A JP2011548901 A JP 2011548901A JP 2012517223 A5 JP2012517223 A5 JP 2012517223A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- region
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 76
- 239000012634 fragment Substances 0.000 claims 31
- 239000000427 antigen Substances 0.000 claims 26
- 102000036639 antigens Human genes 0.000 claims 26
- 108091007433 antigens Proteins 0.000 claims 26
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 claims 17
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 claims 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 8
- 230000026731 phosphorylation Effects 0.000 claims 7
- 238000006366 phosphorylation reaction Methods 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 238000004448 titration Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15141109P | 2009-02-10 | 2009-02-10 | |
| US61/151,411 | 2009-02-10 | ||
| PCT/JP2010/052479 WO2010093055A1 (en) | 2009-02-10 | 2010-02-10 | Anti-mst1r antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012517223A JP2012517223A (ja) | 2012-08-02 |
| JP2012517223A5 true JP2012517223A5 (https=) | 2013-03-28 |
| JP5714511B2 JP5714511B2 (ja) | 2015-05-07 |
Family
ID=42227811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548901A Expired - Fee Related JP5714511B2 (ja) | 2009-02-10 | 2010-02-10 | 抗mst1r抗体およびそれらの使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9403909B2 (https=) |
| EP (1) | EP2396084B1 (https=) |
| JP (1) | JP5714511B2 (https=) |
| KR (1) | KR101745025B1 (https=) |
| CN (1) | CN102438702B (https=) |
| AU (1) | AU2010214301B2 (https=) |
| BR (1) | BRPI1007979A2 (https=) |
| CA (1) | CA2752136C (https=) |
| CO (1) | CO6420322A2 (https=) |
| ES (1) | ES2583281T3 (https=) |
| IL (1) | IL214527A0 (https=) |
| MX (1) | MX2011008456A (https=) |
| NZ (1) | NZ594452A (https=) |
| RU (1) | RU2534890C2 (https=) |
| SG (2) | SG2014009195A (https=) |
| TW (1) | TWI480050B (https=) |
| WO (1) | WO2010093055A1 (https=) |
| ZA (1) | ZA201105725B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356749B (es) * | 2012-04-27 | 2018-06-12 | Daiichi Sankyo Co Ltd | Anticuerpo anti-homologo 4 de roundabout (robo4). |
| TWI909341B (zh) | 2015-09-24 | 2025-12-21 | 日商第一三共股份有限公司 | 抗garp抗體及其製造方法及用途 |
| EP3504244A4 (en) | 2016-08-26 | 2020-08-19 | Agency for Science, Technology and Research | MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES |
| MX2022001812A (es) | 2019-08-12 | 2022-03-11 | Regeneron Pharma | Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos. |
| WO2021066751A1 (en) * | 2019-10-02 | 2021-04-08 | Aslan Pharmaceuticals Pte. Ltd. | Antigen specific binding domains and antibody molecules |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| CA2566647A1 (en) * | 2004-05-13 | 2005-12-22 | Imclone Systems Incorporated | Inhibition of macrophage-stimulating protein receptor (ron) |
| US20060073256A1 (en) * | 2004-06-15 | 2006-04-06 | Frederic Destaillats | Self-foaming liquid creamers and processes |
| JP2008512352A (ja) * | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| UY31478A1 (es) * | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
| MX2010008025A (es) * | 2008-01-22 | 2010-08-04 | Biogen Idec Inc | Anticuerpos ron y usos de los mismos. |
-
2010
- 2010-02-09 TW TW099103887A patent/TWI480050B/zh not_active IP Right Cessation
- 2010-02-10 EP EP10710107.3A patent/EP2396084B1/en not_active Not-in-force
- 2010-02-10 WO PCT/JP2010/052479 patent/WO2010093055A1/en not_active Ceased
- 2010-02-10 CN CN201080016662.8A patent/CN102438702B/zh not_active Expired - Fee Related
- 2010-02-10 RU RU2011137405/10A patent/RU2534890C2/ru not_active IP Right Cessation
- 2010-02-10 KR KR1020117018586A patent/KR101745025B1/ko not_active Expired - Fee Related
- 2010-02-10 SG SG2014009195A patent/SG2014009195A/en unknown
- 2010-02-10 NZ NZ594452A patent/NZ594452A/xx not_active IP Right Cessation
- 2010-02-10 MX MX2011008456A patent/MX2011008456A/es active IP Right Grant
- 2010-02-10 CA CA2752136A patent/CA2752136C/en not_active Expired - Fee Related
- 2010-02-10 BR BRPI1007979A patent/BRPI1007979A2/pt not_active IP Right Cessation
- 2010-02-10 ES ES10710107.3T patent/ES2583281T3/es active Active
- 2010-02-10 AU AU2010214301A patent/AU2010214301B2/en not_active Ceased
- 2010-02-10 JP JP2011548901A patent/JP5714511B2/ja not_active Expired - Fee Related
- 2010-02-10 SG SG2011055175A patent/SG173196A1/en unknown
-
2011
- 2011-08-03 ZA ZA2011/05725A patent/ZA201105725B/en unknown
- 2011-08-08 IL IL214527A patent/IL214527A0/en not_active IP Right Cessation
- 2011-08-10 US US13/206,736 patent/US9403909B2/en not_active Expired - Fee Related
- 2011-08-23 CO CO11106887A patent/CO6420322A2/es active IP Right Grant